Please login to the form below

Not currently logged in

Daily Brief

A rapid round-up of the top pharma, biotech and healthcare news

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

Takeda pharma buildingA rapid round-up of the top pharma, biotech and healthcare news

Daily Brief: Takeda seals $62bn Shire deal, Autolus IPO, Gottlieb warning

A rapid round-up of the top pharma, biotech and healthcare news

Morning brief: New biotech launched, Merck and Moderna expand collaboration and more

A rapid round up of pharma, biotech and healthcare news

Esperion craters as deaths mar atherosclerosis drug study

EsperionBut the company insists its atherosclerosis candidate didn’t cause the deaths

Regeneron’s Dupixent and Praluent falls short

regeneron headquartersBut CEO Len Schleifer says there’s time to fix that

Morning brief: Herzuma launched in Europe, rare disease status for Orchard candidate and more

Gene therapyA rapid round-up of pharma, biotech and healthcare news

J&J pays $140m upfront for cancer-busting virus firm BeneVir

The total value of the deal could go above $1bn if the biotech’s candidates perform well

Business in the USAHealth coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

  • Ho_Ung_KimStanding out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

  • HeadsThe diseased organisation

    Like humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured

Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....